Halozyme Therapeutics, Inc. (BIT:1HALO)

Market Cap	7.93B +17.1%
Revenue (ttm)	1.06B +31.2%
Net Income	507.54M +51.7%
EPS	4.04 +56.7%
Shares Out	n/a
PE Ratio	15.62
Forward PE	9.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	44
Open	n/a
Previous Close	68.34
Day's Range	n/a
52-Week Range	43.67 - 69.00
Beta	n/a
RSI	68.00
Earnings Date	Feb 17, 2026

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 350
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1HALO

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD